Retatrutide – 30 mg
Retatrutide – 20 mg Retatrutide is an experimental triple-hormone receptor agonist (GIP, GLP-1, and glucagon) designed for significant weight loss and type 2 diabetes management. While 20 mg is a high potential quantity found in research vials, clinical trials focused on doses up to 12 mg. It is administered weekly via subcutaneous injection, with trials showing over 20% body weight reduction.
Research Use Only Disclaimer
FOR RESEARCH USE ONLY This product is not intended for human or animal use.Not for medical, diagnostic, therapeutic, metabolic, endocrine, or consumption purposes.No dosage, administration, or biological outcome claims are made or implied.Use is restricted to qualified laboratory research environments only.
❓Frequently Asked Questions
Is retatrutide approved for weight loss or metabolic use?
No. This peptide is supplied strictly for laboratory research purposes.
Does this product include a Certificate of Analysis (COA)?
Yes. Every batch includes a third-party verified COA.
Why is retatrutide supplied in a 20 mg research format?
Higher-mass quantities support extended analytical testing, repeat experimentation, and reference evaluation, not application or use.
Can this compound be used in humans or animals?
No. It is not approved for use in living systems.
How is this product classified?
It is classified solely as a research peptide, not a drug, supplement, or therapeutic agent.